THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

NCT04199468 ↗

Phase 1 Completed 22 enrolled Yale University Brain & Behavior Research Foundation · collab

RandomizedCrossoverDouble-blindBasic science

Summary

The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects, and characterize the interactive effects of ketamine and THC on various electrophysiological (EEG), cognitive, and behavioral outcomes.

Timeline

Start: 2019-09-24
Primary completion: 2022-06-21
Completion: 2022-06-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dronabinol	Other / unclassified	0.015 mg/kg	Intravenous
Subject	Ketamine	Small molecule	0.2 mg/kg	Intravenous

Indications

No indication recorded.